Hospital Acquired Pneumonia Drugs Market Forecast 2024 to 2032
Hospital-acquired pneumonia (HAP) is a type of pneumonia that occurs during or after a hospital stay. It is usually caused by bacteria, including drug-resistant strains, making appropriate antibiotic treatment crucial. The specific choice of drugs depends on various factors such as the suspected pathogens, local antibiotic resistance patterns, and individual patient characteristics. Some of the commonly used drugs for hospital-acquired pneumonia include beta-lactam antibiotics, fluoroquinolones, aminoglycosides, vancomycin, and linezolid.
The Hospital Acquired Pneumonia Drugs Market was valued at USD 2924.63 Million in 2022 and is expected to register a CAGR of 1.5% by 2032.
The rising incidence of hospital-acquired infections is a significant factor driving the global market growth during the forecast period.
Get a Free Sample Copy